Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk Test

11 listopada 2026 zaktualizowane przez: Aether Tech S.L.

Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure: Exercise Substudy (Six-Minute Walk Test) in Ambulatory Patients

This study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient, second by second, according to oxygen saturation (SpO2), heart rate and respiratory rate measured by a pulse oximeter.

Adults with chronic respiratory disease who need oxygen during exertion perform two six-minute walk tests on the same day, 30 minutes apart: one with oxygen adjusted automatically by EMILY.AI and one with a fixed oxygen flow delivered through the same device. The order is randomized and participants do not know which test uses automatic titration.

The study compares the time spent within the target saturation range, desaturation, oxygen use, walking distance, breathlessness and participant preference between the two tests. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.

Przegląd badań

Szczegółowy opis

Background Patients with chronic respiratory disease often desaturate during exertion, and fixed-flow oxygen cannot follow the rapid changes in oxygen demand during walking and recovery. EMILY.AI combines a medical-grade oxygen valve with an edge-computing fuzzy-logic algorithm that sets the oxygen flow every second, with continuous logging of physiological signals and delivered flow.

Design Pilot, pragmatic, single-blind, randomized crossover study at Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain). Each participant performs two supervised six-minute walk tests (6MWT) according to the American Thoracic Society guideline, separated by 30 minutes of rest: one with automatic titration by EMILY.AI and one with a fixed flow set by the physician, delivered through the same device so that the participant cannot tell them apart. The order of the two tests is randomized. Each test includes 6 minutes of walking and 2 minutes of standardized recovery.

Safety The medical team knows the device configuration and supervises the valve throughout each test.

Measurements SpO2, heart rate and respiratory rate are recorded with medical-grade pulse oximeters (Nonin, Masimo or Nihon Kohden models), together with distance walked, Borg dyspnoea score, oxygen delivered and participant-reported comfort, breathlessness and preference.

The protocol FJD-EMILY-23-02 also includes a substudy in the Respiratory Intermediate Care Unit and a substudy in a conventional hospital ward, registered separately.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

24

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

  • Nazwa: Alba Naya Prieto, MD
  • Numer telefonu: +34 915 50 48 00
  • E-mail: alba.naya@fjd.es

Kopia zapasowa kontaktu do badania

  • Nazwa: Sarah Beatrice Heili Frades, MD, PhD
  • Numer telefonu: +34 915 50 48 00
  • E-mail: SHeili@fjd.es

Lokalizacje studiów

      • Madrid, Hiszpania, 28040
        • Rekrutacyjny
        • Hospital Universitario Fundación Jiménez Díaz
        • Kontakt:
          • Sarah Beatrice Heili Frades Zimmermann MD, PhD
          • Numer telefonu: +34 915 50 48 00
          • E-mail: SHeili@fjd.es
        • Kontakt:
          • Alba Naya Prieto, MD
          • Numer telefonu: +34 915 50 48 00
          • E-mail: alba.naya@fjd.es
        • Główny śledczy:
          • Sarah Beatrice Heili Frades Zimmermann, MD, PhD

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

40 lat do 90 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Aged 40 to 90 years with a chronic respiratory disease.
  • Indication for exertional oxygen therapy, defined as SpO2 below 88% during a six-minute walk test and/or resting respiratory failure (PaO2 below 60 mmHg).
  • Able to understand the study and sign informed consent.

Exclusion Criteria:

  • Decompensated acute or chronic disease with severe organ involvement, such as cardiovascular disease.
  • Musculoskeletal or neurological disease preventing stable and safe walking.
  • Comorbidities or treatments that, by intensity or dose, limit performance of the tests or interpretation of the results (such as alcohol use, beta-blockers, or other neurological or psychiatric drugs).
  • Walking limitation preventing the six-minute walk test, or cardiovascular or connective tissue disease limiting accurate transcutaneous pulse oximetry.
  • Pregnancy or breastfeeding (women of childbearing potential require a negative pregnancy test at screening).

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Zadanie krzyżowe
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: EMILY.AI first, then fixed flow

First 6MWT with automatic titration by EMILY.AI; after 30 minutes of rest, second 6MWT with fixed-flow oxygen through the same device.

Investigational smart oxygen valve with an embedded fuzzy-logic algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery. Other names: EMILY.AI Smart Valve

Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration.

Eksperymentalny: Fixed flow first, then EMILY.AI

First 6MWT with fixed-flow oxygen through the device; after 30 minutes of rest, second 6MWT with automatic titration by EMILY.AI.

Investigational smart oxygen valve with an embedded fuzzy-logic algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery. Other names: EMILY.AI Smart Valve

Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of time with SpO2 within the target range
Ramy czasowe: Day 1

Percentage of test time (6 minutes of walking plus 2 minutes of recovery) with SpO2, measured by pulse oximetry, within the predefined target range (88-92%), without delivering oxygen while SpO2 is above the range. Compared between the test with automatic titration by EMILY.AI and the test with fixed flow.

Day 1

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percentage of test time with SpO2 below 88%
Ramy czasowe: Day 1

Percentage of test time (walking and recovery) with SpO2 below 88%, compared between conditions.

Day 1
Number of desaturation episodes with SpO2 below 88%
Ramy czasowe: Day 1

Number of episodes per test in which SpO2 falls below 88%, compared between conditions.

Day 1
Time to start of oxygen flow correction
Ramy czasowe: Day 1

Time in seconds from SpO2 leaving the target range (88-96%) to the start of an oxygen flow change, compared between conditions.

Day 1
Time to return of SpO2 to the target range
Ramy czasowe: Day 1

Time in seconds from SpO2 leaving the target range (88-96%) to its return to the range, compared between conditions.

Day 1
Percentage of test time with oxygen delivered while SpO2 is above 92%
Ramy czasowe: Day 1

Percentage of test time (walking and recovery) during which oxygen is delivered while SpO2 is above 92%, compared between conditions.

Day 1
Number of episodes with oxygen delivered while SpO2 is above 92%
Ramy czasowe: Day 1

Number of episodes per test in which oxygen is delivered while SpO2 is above 92%, compared between conditions.

Day 1
Total oxygen delivered
Ramy czasowe: Day 1

Total volume of oxygen delivered (litres) during each test including recovery, compared between conditions.

Day 1
Mean oxygen flow
Ramy czasowe: Day 1

Mean oxygen flow (litres per minute) delivered during each test including recovery, compared between conditions.

Day 1
Six-minute walk distance
Ramy czasowe: Day 1

Distance walked (metres), compared between conditions.

Day 1
Change in dyspnoea measured with the modified Borg Dyspnoea Scale
Ramy czasowe: Day 1: before and immediately after each six-minute walk test

Change from the start to the end of each test in dyspnoea measured with the modified Borg Dyspnoea Scale, which ranges from 0 (no breathlessness at all) to 10 (maximal breathlessness). Higher scores mean a worse outcome. Compared between conditions.

Day 1: before and immediately after each six-minute walk test
Maximum heart rate
Ramy czasowe: Day 1

Maximum heart rate (beats per minute) during each test, compared between conditions.

Day 1
Maximum respiratory rate
Ramy czasowe: Day 1

Maximum respiratory rate (breaths per minute) during each test, compared between conditions.

Day 1
Perceived difference in exercise capacity between the two tests
Ramy czasowe: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in your exercise capacity in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Perceived difference in breathlessness between the two tests
Ramy czasowe: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in shortness of breath in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Perceived difference in comfort of oxygen delivery between the two tests
Ramy czasowe: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in the comfort of oxygen delivery in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference between the two oxygen delivery systems
Ramy czasowe: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Do you prefer either of the two oxygen systems used in the tests?", and, if so, which one. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference for continuous automatic flow regulation at home
Ramy czasowe: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to regulate the oxygen flow continuously?". Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference for telemonitored home oxygen
Ramy czasowe: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to be telemonitored by the medical team?". Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Sarah Beatrice Heili Frades, MD, PhD, MD, PhD, Hospital Universitario Fundación Jiménez Díaz

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

15 kwietnia 2026

Zakończenie podstawowe (Szacowany)

20 grudnia 2026

Ukończenie studiów (Szacowany)

20 grudnia 2026

Daty rejestracji na studia

Pierwszy przesłany

28 października 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 listopada 2026

Pierwszy wysłany (Rzeczywisty)

16 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

11 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIEZDECYDOWANY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj